Escitalopram and citalopram: The unexpected role of the R-enantiomer;Escitalopram et citalopram: Le rôle inattendu de l'é nantiomère R

Encephale

Volumn 33, Issue 2, 2007, Pages 179-187

  Jacquot, C ^a   David, D J ^a   Gardier, A M ^a   Sanchez C ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

Citalopram; Depression; Escitalopram; R enantiomer; SSRI

Indexed keywords

CITALOPRAM; ESCITALOPRAM;

ALLOSTERISM; BLOOD BRAIN BARRIER; DEPRESSION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENANTIOMER; FRONTAL CORTEX; NONHUMAN; RECEPTOR AFFINITY; REVIEW;

EID: 34249100500     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0013-7006(07)91548-1     Document Type: Article

References (17)

1. COSTA E, AUTA J, GRAYSON DR et al. GABAA receptors and benzodiazepines : a role for dendritic resident subunit mRNAs. Neuropharmacology 2002 ; 43 : 925-37.
2. FABRE V, HAMON M. De nouvelles données pour appréhender les mécanismes d'action des antidépresseurs : l'apport du Escitalopram. Encéphale 2003 ; 29 : 259-65.
3. MACDONALD JF, MODY I, SALTER MW et al. The regulation of NMDA receptors in the central nervous system. Prog Neuro Psychopharmacol Biol Psychiatry 1989 ; 13 : 481-8.
4. MAELICKE A, SCHRATTENHOLZ A, SAMOCHOCKI M et al. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behavior Brain Res 2000 ; 113 : 199-206.
5. MONTGOMERY SA, LOFT H, SÁNCHEZ C et al. Escitalopram (S-enantiomer of citalopram) : clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicology 2001 ; 88 : 282-6.
6. MØRK A, KREILGAARD M, SÁNCHEZ C et al. In vitro and in vivo effects of citalopram and its enantiomers on the serotonin uptake transporter. Eur Neuropsychopharmacology 2002 ; 12 (Suppl 3) : S224.
7. MØRK A, KREILILGARD M, SÁNCHEZ C. The R-enantiomer of citalopram counteracts escitaloptram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003 ; 45 : 167-73.
8. OWENS MJ, KNIGHT DL, NEMEROFF CB. Second-generation SSRIs : human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001 ; 50 : 345-50.
9. 3H] citalopram binding to the 5-HT transporter from brain and platelets. Eur J Pharmacology Mol Pharmacology 1991 ; 206 : 243-50.
10. SÁNCHEZ C, BERGQVIST PBF, BRENNUM LT et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 2003a ; 167 : 353-62.
11. SÁNCHEZ C, GRUCA P, PAPP M. R-citalopram counteracts the antidepresant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacology 2003b ; 14 : 465-70.
12. SÁNCHEZ C. R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Europ J Pharmacology 2003c ; 464 : 155-8.
13. SÁNCHEZ C, BØGESØ KP, EBERT B et al. Escitalopram versus citalopram : the surprising role of the R-enantiomer. Psychopharmacology 2004 ; 174 : 163-76.
14. WIBORG O, SÁNCHEZ C. R-citalopram decreases the association of [3H]-S-citalopram with the human serotonin transporter by an allosteric mechanism. Europ Neuropsychopharmacology 2003 ; 13S4 : S216.
15. WILLNER P. Validity, reliability, and utility of the chronic mild stress model of depression : a 10-year review and evaluation. Psychopharmacology 1997 ; 134 : 319-29.
16. YAMAKURA T, SHIMOJI K. Subunit- and site-specific pharmaco-logy of the NMDA receptor channel. Prog Neurobiology 1999 ; 59 : 279-98.
17. ZHENG F, ERREGER K, LOW CM et al. Allosteric interaction between the amino terminal domain and the ligand binding domain of NR2A. Nat Neuroscience 2001 ; 4 : 894-901.